Congenital Hyperinsulinism Treatment Drugs Market - Global Outlook and Forecast 2021-2027

March 2021 | 92 pages | ID: CDAAE9B12F9DEN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Congenital Hyperinsulinism Treatment Drugs in Global, including the following market information:

Global Congenital Hyperinsulinism Treatment Drugs Market Revenue, 2016-2021, 2022-2027, ($ millions)

Global top five companies in 2020 (%)

The global Congenital Hyperinsulinism Treatment Drugs market was valued at XX million in 2020 and is projected to reach US$ XX million by 2027, at a CAGR of XX% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Congenital Hyperinsulinism Treatment Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Congenital Hyperinsulinism Treatment Drugs Market, By Type, 2016-2021, 2022-2027 ($ millions)

Global Congenital Hyperinsulinism Treatment Drugs Market Segment Percentages, By Type, 2020 (%)

• Diazoxide
• Octreotide
• Glucagon

China Congenital Hyperinsulinism Treatment Drugs Market, By Application, 2016-2021, 2022-2027 ($ millions)

China Congenital Hyperinsulinism Treatment Drugs Market Segment Percentages, By Application, 2020 (%)

• Hospital
• Clinic
• Other

Global Congenital Hyperinsulinism Treatment Drugs Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)

Global Congenital Hyperinsulinism Treatment Drugs Market Segment Percentages, By Region and Country, 2020 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Total Congenital Hyperinsulinism Treatment Drugs Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)

Total Congenital Hyperinsulinism Treatment Drugs Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:

• Novo Nordisk
• Eli Lilly
• Fresenius Kabi
• Taj Pharmaceuticals
• Xeris Pharmaceuticals
• Novartis
• IVAX Pharmaceuticals
• Sun Pharmaceutical
• Chengdu Tiantaishan Pharmaceutical
• Sihuan Pharmaceutical Holdings Group

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Congenital Hyperinsulinism Treatment Drugs Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Congenital Hyperinsulinism Treatment Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL CONGENITAL HYPERINSULINISM TREATMENT DRUGS OVERALL MARKET SIZE

2.1 Global Congenital Hyperinsulinism Treatment Drugs Market Size: 2021 VS 2027
2.2 Global Congenital Hyperinsulinism Treatment Drugs Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Congenital Hyperinsulinism Treatment Drugs Players in Global Market
3.2 Top Global Congenital Hyperinsulinism Treatment Drugs Companies Ranked by Revenue
3.3 Global Congenital Hyperinsulinism Treatment Drugs Revenue by Companies
3.4 Top 3 and Top 5 Congenital Hyperinsulinism Treatment Drugs Companies in Global Market, by Revenue in 2020
3.5 Global Companies Congenital Hyperinsulinism Treatment Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Congenital Hyperinsulinism Treatment Drugs Players in Global Market
  3.6.1 List of Global Tier 1 Congenital Hyperinsulinism Treatment Drugs Companies
  3.6.2 List of Global Tier 2 and Tier 3 Congenital Hyperinsulinism Treatment Drugs Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Global Congenital Hyperinsulinism Treatment Drugs Market Size Markets, 2021 & 2027
  4.1.2 Diazoxide
  4.1.3 Octreotide
  4.1.4 Glucagon
4.2 By Type - Global Congenital Hyperinsulinism Treatment Drugs Revenue & Forecasts
  4.2.1 By Type - Global Congenital Hyperinsulinism Treatment Drugs Revenue, 2016-2021
  4.2.2 By Type - Global Congenital Hyperinsulinism Treatment Drugs Revenue, 2022-2027
  4.2.3 By Type - Global Congenital Hyperinsulinism Treatment Drugs Revenue Market Share, 2016-2027

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Congenital Hyperinsulinism Treatment Drugs Market Size, 2021 & 2027
  5.1.2 Hospital
  5.1.3 Clinic
  5.1.4 Other
5.2 By Application - Global Congenital Hyperinsulinism Treatment Drugs Revenue & Forecasts
  5.2.1 By Application - Global Congenital Hyperinsulinism Treatment Drugs Revenue, 2016-2021
  5.2.2 By Application - Global Congenital Hyperinsulinism Treatment Drugs Revenue, 2022-2027
  5.2.3 By Application - Global Congenital Hyperinsulinism Treatment Drugs Revenue Market Share, 2016-2027

6 SIGHTS BY REGION

6.1 By Region - Global Congenital Hyperinsulinism Treatment Drugs Market Size, 2021 & 2027
6.2 By Region - Global Congenital Hyperinsulinism Treatment Drugs Revenue & Forecasts
  6.2.1 By Region - Global Congenital Hyperinsulinism Treatment Drugs Revenue, 2016-2021
  6.2.2 By Region - Global Congenital Hyperinsulinism Treatment Drugs Revenue, 2022-2027
  6.2.3 By Region - Global Congenital Hyperinsulinism Treatment Drugs Revenue Market Share, 2016-2027
6.3 North America
  6.3.1 By Country - North America Congenital Hyperinsulinism Treatment Drugs Revenue, 2016-2027
  6.3.2 US Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
  6.3.3 Canada Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
  6.3.4 Mexico Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
6.4 Europe
  6.4.1 By Country - Europe Congenital Hyperinsulinism Treatment Drugs Revenue, 2016-2027
  6.4.2 Germany Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
  6.4.3 France Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
  6.4.4 U.K. Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
  6.4.5 Italy Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
  6.4.6 Russia Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
  6.4.7 Nordic Countries Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
  6.4.8 Benelux Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
6.5 Asia
  6.5.1 By Region - Asia Congenital Hyperinsulinism Treatment Drugs Revenue, 2016-2027
  6.5.2 China Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
  6.5.3 Japan Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
  6.5.4 South Korea Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
  6.5.5 Southeast Asia Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
  6.5.6 India Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
6.6 South America
  6.6.1 By Country - South America Congenital Hyperinsulinism Treatment Drugs Revenue, 2016-2027
  6.6.2 Brazil Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
  6.6.3 Argentina Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Revenue, 2016-2027
  6.7.2 Turkey Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
  6.7.3 Israel Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
  6.7.4 Saudi Arabia Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027
  6.7.5 UAE Congenital Hyperinsulinism Treatment Drugs Market Size, 2016-2027

7 PLAYERS PROFILES

7.1 Novo Nordisk
  7.1.1 Novo Nordisk Corporate Summary
  7.1.2 Novo Nordisk Business Overview
  7.1.3 Novo Nordisk Congenital Hyperinsulinism Treatment Drugs Major Product Offerings
  7.1.4 Novo Nordisk Congenital Hyperinsulinism Treatment Drugs Revenue in Global (2016-2021)
  7.1.5 Novo Nordisk Key News
7.2 Eli Lilly
  7.2.1 Eli Lilly Corporate Summary
  7.2.2 Eli Lilly Business Overview
  7.2.3 Eli Lilly Congenital Hyperinsulinism Treatment Drugs Major Product Offerings
  7.2.4 Eli Lilly Congenital Hyperinsulinism Treatment Drugs Revenue in Global (2016-2021)
  7.2.5 Eli Lilly Key News
7.3 Fresenius Kabi
  7.3.1 Fresenius Kabi Corporate Summary
  7.3.2 Fresenius Kabi Business Overview
  7.3.3 Fresenius Kabi Congenital Hyperinsulinism Treatment Drugs Major Product Offerings
  7.3.4 Fresenius Kabi Congenital Hyperinsulinism Treatment Drugs Revenue in Global (2016-2021)
  7.3.5 Fresenius Kabi Key News
7.4 Taj Pharmaceuticals
  7.4.1 Taj Pharmaceuticals Corporate Summary
  7.4.2 Taj Pharmaceuticals Business Overview
  7.4.3 Taj Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Major Product Offerings
  7.4.4 Taj Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Revenue in Global (2016-2021)
  7.4.5 Taj Pharmaceuticals Key News
7.5 Xeris Pharmaceuticals
  7.5.1 Xeris Pharmaceuticals Corporate Summary
  7.5.2 Xeris Pharmaceuticals Business Overview
  7.5.3 Xeris Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Major Product Offerings
  7.5.4 Xeris Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Revenue in Global (2016-2021)
  7.5.5 Xeris Pharmaceuticals Key News
7.6 Novartis
  7.6.1 Novartis Corporate Summary
  7.6.2 Novartis Business Overview
  7.6.3 Novartis Congenital Hyperinsulinism Treatment Drugs Major Product Offerings
  7.6.4 Novartis Congenital Hyperinsulinism Treatment Drugs Revenue in Global (2016-2021)
  7.6.5 Novartis Key News
7.7 IVAX Pharmaceuticals
  7.7.1 IVAX Pharmaceuticals Corporate Summary
  7.7.2 IVAX Pharmaceuticals Business Overview
  7.7.3 IVAX Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Major Product Offerings
  7.4.4 IVAX Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Revenue in Global (2016-2021)
  7.7.5 IVAX Pharmaceuticals Key News
7.8 Sun Pharmaceutical
  7.8.1 Sun Pharmaceutical Corporate Summary
  7.8.2 Sun Pharmaceutical Business Overview
  7.8.3 Sun Pharmaceutical Congenital Hyperinsulinism Treatment Drugs Major Product Offerings
  7.8.4 Sun Pharmaceutical Congenital Hyperinsulinism Treatment Drugs Revenue in Global (2016-2021)
  7.8.5 Sun Pharmaceutical Key News
7.9 Chengdu Tiantaishan Pharmaceutical
  7.9.1 Chengdu Tiantaishan Pharmaceutical Corporate Summary
  7.9.2 Chengdu Tiantaishan Pharmaceutical Business Overview
  7.9.3 Chengdu Tiantaishan Pharmaceutical Congenital Hyperinsulinism Treatment Drugs Major Product Offerings
  7.9.4 Chengdu Tiantaishan Pharmaceutical Congenital Hyperinsulinism Treatment Drugs Revenue in Global (2016-2021)
  7.9.5 Chengdu Tiantaishan Pharmaceutical Key News
7.10 Sihuan Pharmaceutical Holdings Group
  7.10.1 Sihuan Pharmaceutical Holdings Group Corporate Summary
  7.10.2 Sihuan Pharmaceutical Holdings Group Business Overview
  7.10.3 Sihuan Pharmaceutical Holdings Group Congenital Hyperinsulinism Treatment Drugs Major Product Offerings
  7.10.4 Sihuan Pharmaceutical Holdings Group Congenital Hyperinsulinism Treatment Drugs Revenue in Global (2016-2021)
  7.10.5 Sihuan Pharmaceutical Holdings Group Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Congenital Hyperinsulinism Treatment Drugs Market Opportunities & Trends in Global Market
Table 2. Congenital Hyperinsulinism Treatment Drugs Market Drivers in Global Market
Table 3. Congenital Hyperinsulinism Treatment Drugs Market Restraints in Global Market
Table 4. Key Players of Congenital Hyperinsulinism Treatment Drugs in Global Market
Table 5. Top Congenital Hyperinsulinism Treatment Drugs Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Congenital Hyperinsulinism Treatment Drugs Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Congenital Hyperinsulinism Treatment Drugs Revenue Share by Companies, 2016-2021
Table 8. Global Companies Congenital Hyperinsulinism Treatment Drugs Product Type
Table 9. List of Global Tier 1 Congenital Hyperinsulinism Treatment Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Congenital Hyperinsulinism Treatment Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – Global Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Congenital Hyperinsulinism Treatment Drugs Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - Congenital Hyperinsulinism Treatment Drugs Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application – Global Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - Congenital Hyperinsulinism Treatment Drugs Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - Congenital Hyperinsulinism Treatment Drugs Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region – Global Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global Congenital Hyperinsulinism Treatment Drugs Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global Congenital Hyperinsulinism Treatment Drugs Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2022-2027
Table 30. Novo Nordisk Corporate Summary
Table 31. Novo Nordisk Congenital Hyperinsulinism Treatment Drugs Product Offerings
Table 32. Novo Nordisk Congenital Hyperinsulinism Treatment Drugs Revenue (US$, Mn), (2016-2021)
Table 33. Eli Lilly Corporate Summary
Table 34. Eli Lilly Congenital Hyperinsulinism Treatment Drugs Product Offerings
Table 35. Eli Lilly Congenital Hyperinsulinism Treatment Drugs Revenue (US$, Mn), (2016-2021)
Table 36. Fresenius Kabi Corporate Summary
Table 37. Fresenius Kabi Congenital Hyperinsulinism Treatment Drugs Product Offerings
Table 38. Fresenius Kabi Congenital Hyperinsulinism Treatment Drugs Revenue (US$, Mn), (2016-2021)
Table 39. Taj Pharmaceuticals Corporate Summary
Table 40. Taj Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Product Offerings
Table 41. Taj Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Revenue (US$, Mn), (2016-2021)
Table 42. Xeris Pharmaceuticals Corporate Summary
Table 43. Xeris Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Product Offerings
Table 44. Xeris Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Revenue (US$, Mn), (2016-2021)
Table 45. Novartis Corporate Summary
Table 46. Novartis Congenital Hyperinsulinism Treatment Drugs Product Offerings
Table 47. Novartis Congenital Hyperinsulinism Treatment Drugs Revenue (US$, Mn), (2016-2021)
Table 48. IVAX Pharmaceuticals Corporate Summary
Table 49. IVAX Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Product Offerings
Table 50. IVAX Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Revenue (US$, Mn), (2016-2021)
Table 51. Sun Pharmaceutical Corporate Summary
Table 52. Sun Pharmaceutical Congenital Hyperinsulinism Treatment Drugs Product Offerings
Table 53. Sun Pharmaceutical Congenital Hyperinsulinism Treatment Drugs Revenue (US$, Mn), (2016-2021)
Table 54. Chengdu Tiantaishan Pharmaceutical Corporate Summary
Table 55. Chengdu Tiantaishan Pharmaceutical Congenital Hyperinsulinism Treatment Drugs Product Offerings
Table 56. Chengdu Tiantaishan Pharmaceutical Congenital Hyperinsulinism Treatment Drugs Revenue (US$, Mn), (2016-2021)
Table 57. Sihuan Pharmaceutical Holdings Group Corporate Summary
Table 58. Sihuan Pharmaceutical Holdings Group Congenital Hyperinsulinism Treatment Drugs Product Offerings
Table 59. Sihuan Pharmaceutical Holdings Group Congenital Hyperinsulinism Treatment Drugs Revenue (US$, Mn), (2016-2021)

List Of Figures

LIST OF FIGURES

Figure 1. Congenital Hyperinsulinism Treatment Drugs Segment by Type
Figure 2. Congenital Hyperinsulinism Treatment Drugs Segment by Application
Figure 3. Global Congenital Hyperinsulinism Treatment Drugs Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Congenital Hyperinsulinism Treatment Drugs Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Congenital Hyperinsulinism Treatment Drugs Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Congenital Hyperinsulinism Treatment Drugs Revenue in 2020
Figure 8. By Type - Global Congenital Hyperinsulinism Treatment Drugs Revenue Market Share, 2016-2027
Figure 9. By Application - Global Congenital Hyperinsulinism Treatment Drugs Revenue Market Share, 2016-2027
Figure 10. By Region - Global Congenital Hyperinsulinism Treatment Drugs Revenue Market Share, 2016-2027
Figure 11. By Country - North America Congenital Hyperinsulinism Treatment Drugs Revenue Market Share, 2016-2027
Figure 12. US Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 13. Canada Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe Congenital Hyperinsulinism Treatment Drugs Revenue Market Share, 2016-2027
Figure 16. Germany Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 17. France Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 19. Italy Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 20. Russia Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia Congenital Hyperinsulinism Treatment Drugs Revenue Market Share, 2016-2027
Figure 24. China Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 25. Japan Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 28. India Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America Congenital Hyperinsulinism Treatment Drugs Revenue Market Share, 2016-2027
Figure 30. Brazil Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Revenue Market Share, 2016-2027
Figure 33. Turkey Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 34. Israel Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 36. UAE Congenital Hyperinsulinism Treatment Drugs Revenue, (US$, Mn), 2016-2027
Figure 37. Novo Nordisk Congenital Hyperinsulinism Treatment Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Eli Lilly Congenital Hyperinsulinism Treatment Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. Fresenius Kabi Congenital Hyperinsulinism Treatment Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. Taj Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. Xeris Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Novartis Congenital Hyperinsulinism Treatment Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 43. IVAX Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 44. Sun Pharmaceutical Congenital Hyperinsulinism Treatment Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 45. Chengdu Tiantaishan Pharmaceutical Congenital Hyperinsulinism Treatment Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 46. Sihuan Pharmaceutical Holdings Group Congenital Hyperinsulinism Treatment Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)